Printer Friendly

FDA CLEARS NABI'S QC-HEPATITIS PRODUCT FOR MARKETING

 FDA CLEARS NABI'S QC-HEPATITIS PRODUCT FOR MARKETING
 MIAMI, March 19 /PRNewswire/ -- North American Biologicals, Inc. ("NABI") (NASDAQ: NBIO) today announced that its QC-Hepatitis(tm) Quality Assurance Reagent for in vitro diagnostic use has been cleared for commercial distribution by the Food and Drug Administration. QC-Hepatitis is the first multi-level, multi-constituent reagent cleared by the FDA to be used as an external control to promote the accuracy of hepatitis testing of the blood supply and blood products. In November 1991, NABI received FDA clearance of its QC-HIV(tm) Quality Assurance Reagent and will now be marketing both products to reference laboratories, blood bank laboratories, and diagnostic product companies.
 "We view QC-Hepatitis as another significant addition to our high-value-added portfolio of proprietary products derived from plasma," commented David J. Gury, president of NABI. "NABI is clearly positioned as a leading provider of Quality Assurance Reagents for infectious diseases, and we plan to enhance this role through the development of additional reagents," Gury added.
 NABI management noted that hepatitis is escalating worldwide and that the new QC-Hepatitis product will be particularly useful because it is applicable to the Hepatitis B and C strains of the virus, including the antibody to Hepatitis B Core antigen.
 The market for Hepatitis and HIV Quality Assurance Reagents is estimated at approximately $25 million annually in the United States. The market is expected to grow in coming years due to increasing disease incidence and to the recently instituted regulatory requirements in both the U.S. and Europe mandating testing for additional strains of hepatitis in blood and plasma. In addition, regulations published in February 1992 relating to the Clinical Laboratory Improvement Act of 1988 make it necessary for laboratories to use independent external controls to promote the quality of their testing.
 North American Biologicals, Inc., headquartered in Miami, is the world's largest independent provider of human blood plasma elements to the health care industry, a major AIDS screening laboratory, and a leading supplier of control products used to promote accuracy in blood testing laboratories.
 -0- 3/19/92
 /CONTACT: David J. Gury, president, or Alfred J. Fernandez, CFO, of North American Biologicals, 305-628-0080; or Marcia A. Kean of Feinstein Partners, 617-577-8110, for North American Biologicals/
 (NBIO) CO: North American Biologicals, Inc. ST: Florida IN: MTC SU:


TM-EG -- NE004 -- 9557 03/19/92 09:51 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:387
Previous Article:CENTRAL AND SOUTH WEST NAMES DIRECTOR OF MARKETING AND BUSINESS DEVELOPMENT
Next Article:FEDERAL REALTY INVESTMENT TRUST ANNOUNCES 118TH CONSECUTIVE DIVIDEND
Topics:


Related Articles
FDA CLEARS NABI'S QC-HIV FOR MARKETING
NABI SEEKS TO MARKET THIRD VIROCHEQC DIAGNOSTIC PRODUCT; VIROCHEQC I SERVES AS MULTI-CONSTITUENT CONTROL FOR HIV 1&2 AND HEPATITIS MARKERS
NABI ISSUES STATEMENT REGARDING FDA LETTER; ERRORS CITED WERE ALL INTERNAL AND HAD BEEN CORRECTED
NABI Commences Expanded Clinical Program for New H-BIG(R) Formulation for Hepatitis B Prophylaxis
NABI to Report Non-Recurring Charge for Third Quarter 1996
Nabi(R) Receives FDA Approval for Nabi-HB(TM).
Nabi-HB(TM) Launched.
FDA Approves Production Of Initial Lots At Nabi Biopharmaceuticals Boca Raton Facility.
Nabi Biopharmaceuticals Receives Complete Response From FDA On Nabi-HB(R) Intravenous, Hepatitis B Antibody Product Biological License Application...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters